These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1391428)

  • 1. Fluosol DA-20% in treatment of severe anemia: ongoing studies in 52 patients.
    Spence RK; McCoy S; Costabile J; Norcross ED; Pello M; Alexander J; Atabek U; Wisdom C; Camishion R
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):1069. PubMed ID: 1391428
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical experience with Fluosol-DA (20%) in the United States.
    Tremper KK; Levine EM; Waxman K
    Int Anesthesiol Clin; 1985; 23(1):185-97. PubMed ID: 3884514
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%).
    Tremper KK; Lapin R; Levine E; Friedman A; Shoemaker WC
    Crit Care Med; 1980 Dec; 8(12):738-41. PubMed ID: 7449405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfluorochemical emulsion oxygen transport fluids: a clinical review.
    Tremper KK; Anderson ST
    Annu Rev Med; 1985; 36():309-13. PubMed ID: 3888055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty.
    Kerins DM
    Am J Med Sci; 1994 Mar; 307(3):218-21. PubMed ID: 8160713
    [No Abstract]   [Full Text] [Related]  

  • 6. Present status of clinical studies of Fluosol-DA (20%) in Japan.
    Mitsuno T; Ohyanagi H
    Int Anesthesiol Clin; 1985; 23(1):169-84. PubMed ID: 3980104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluosol DA-20 in the treatment of severe anemia: randomized, controlled study of 46 patients.
    Spence RK; McCoy S; Costabile J; Norcross ED; Pello MJ; Alexander JB; Wisdom C; Camishion RC
    Crit Care Med; 1990 Nov; 18(11):1227-30. PubMed ID: 1699704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients.
    Stefaniszyn HJ; Wynands JE; Salerno TA
    J Cardiovasc Surg (Torino); 1985; 26(4):337-42. PubMed ID: 4019576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which is the foreseeable clinical application of oxygen-carrying blood substitutes (fluorocarbons and hemoglobin solutions)? Which impact are they likely to have on the activity of blood services?
    Vox Sang; 1982 Feb; 42(2):97-109. PubMed ID: 7064434
    [No Abstract]   [Full Text] [Related]  

  • 10. Perfluorocarbons as blood substitutes: the early years. Experience with Fluosol DA-20% in the 1980s.
    Spence RK; Norcross ED; Costabile J; McCoy S; Cernaianu AC; Alexander JB; Pello MJ; Atabek U; Camishion RC
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):955-63. PubMed ID: 7849967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluosol-DA as a red-cell substitute in acute anemia.
    Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Langdale LA; Krause LM; Rice CL; Chamberlin WH; Moss GS
    N Engl J Med; 1986 Jun; 314(26):1653-6. PubMed ID: 3713771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hemodilution with dextran, stroma-free hemoglobin solution and fluosol-DA on experimental myocardial ischemia in the dog.
    Biro GP
    Bibl Haematol; 1981; (47):54-69. PubMed ID: 6175307
    [No Abstract]   [Full Text] [Related]  

  • 13. Polyhemoglobin and fluorocarbon as blood substitutes.
    Moss GS; Gould SA; Sehgal LR; Rosen AL; Sehgal HL
    Biomater Artif Cells Artif Organs; 1987; 15(2):333-6. PubMed ID: 3447649
    [No Abstract]   [Full Text] [Related]  

  • 14. The protective effect of mannitol and perfluorochemicals on hemorrhagic infarction: an experimental study.
    Kagawa S; Koshu K; Yoshimoto T; Suzuki J
    Surg Neurol; 1982 Jan; 17(1):66-70. PubMed ID: 6803373
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular effects of various colloidal solutions during major abdominal surgery.
    Nishimura N; Hiranuma N; Sugi T
    Crit Care Med; 1983 Dec; 11(12):940-2. PubMed ID: 6196154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a hemoglobin substitute in the anemic Jehovah's Witness patient.
    Marelli TR
    Crit Care Nurse; 1994 Feb; 14(1):31-8. PubMed ID: 8194324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a blood substitute (Fluosol-DA, 20%) on cerebral ischemia.
    Oda Y; Handa H; Nagasawa S; Naruo Y; Asato R; Yonekawa Y
    Neurol Res; 1982; 4(1-2):35-45. PubMed ID: 6127644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluosol-DA as a red-cell substitute in acute anemia.
    N Engl J Med; 1986 Dec; 315(26):1677-8. PubMed ID: 3785341
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical experience with Fluosol-DA.
    Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Moss GS
    Prog Clin Biol Res; 1983; 122():331-42. PubMed ID: 6878375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the clinical studies of anemia treated with the perfluorochemical emulsion: Fluosol DA 20%.
    Tremper KK
    Prog Clin Biol Res; 1983; 122():307-13. PubMed ID: 6348785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.